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The GLAM assay, a combined flow cytometric immunofluorescence
test that simultaneously detects antibodies to granulocytes, lym-
phocytes, and monocytes, was used in the investigation of autoim-
mune neutropenia. This method avoids the need for a succession of
immunofluorescence tests, first against granulocytes and then
against lymphocytes, in order to distinguish granulocyte-specific
from granulocyte/lymphocyte-reactive antibodies, such as noncom-
plement-fixing anti-HLA sera. Samples from 18 patients with a sus-
pected diagnosis of autoimmune neutropenia were referred for
investigation. Leukocytes were harvested in sufficient quantities
from 10 of the patients such that neutrophil and lymphocyte direct
antiglobulin tests (DATs) and antibody screening and identification
could be undertaken (in one case the results were inconclusive).
Only three of these 10 patients had DAT-positive granulocytes, and
one of these three also had DAT-positive lymphocytes. One further
patient demonstrated DAT-positive lymphocytes in the absence of
granulocyte-bound IgG, despite a presumed diagnosis of autoim-
mune neutropenia, rather than pancytopenia. This was the only
patient in this cohort who had demonstrable leukocyte antibodies
reacting with lymphocytes but not granulocytes. Of the remaining
eight patients (not evaluable for granulocyte or lymphocyte DATs),
five had free leukocyte antibodies in the serum; three of these five
had both granulocyte- and lymphocyte-reactive antibodies free in the
serum and two only had granulocyte-specific antibodies. Immuno-
hematology 1996;12:164–168.
Autoimmune neutropenia is generally diagnosed
using a granulocyte immunofluorescence test (GIFT)1
with an ultraviolet (UV) microscope. Brough et al.2
recently described an assay, a combined immunofluo-
rescence test assessed by flow cytometry, that simulta-
neously detects antibodies to granulocytes,
lymphocytes, and monocytes (GLAM). This method
avoids the need for a succession of immunofluorescence
tests, first against granulocytes and then against lym-
phocytes, in order to distinguish granulocyte-specific
from granulocyte-reactive antibodies. The latter are
potentially noncomplement-fixing HLA antibodies,
which are also detected in the GIFT and can be confused
with true granulocyte-specific antibodies in the absence
of confirmatory lymphocyte immunofluorescence tests.
We report our experience with the GLAM assay on
samples from neutropenic patients, outlining the facili-
ty of the assay in discriminating leukocyte- from granu-
locyte-specific antibodies, and whether they are
cell-bound or “free” in serum. We also present data on
the mixtures of such antibodies encountered in patients




Samples from 18 patients with a suspected diagnosis
of autoimmune neutropenia were referred to Leeds
Blood Centre, West Yorkshire, UK.
Leukocytes were harvested in sufficient quantities
from 10 of the 18 patients (cases 1–3 and 9–15 in Table
1) so that neutrophil and lymphocyte direct antiglobu-
lin tests (DATs), autoantibody testing, and NA1 and NB1
typing could be undertaken simultaneously.
Preparation of samples for analysis
Samples of whole blood (either from the patient or
from donors selected for inclusion in leukocyte antibody
identification panels) were warmed for 2 minutes at
37˚C in a waterbath, then fixed in formol saline (a dilu-
tion of formaldehyde in phosphate-buffered saline
[PBS]) prior to lysis of red blood cells in Tris-buffered
ammonium chloride. Blood samples were usually pro-
cessed within 24 hours, since fresh samples generally
gave superior flow cytometric discrimination of the var-
ious leukocyte populations. For normal donors, 4 mL
EDTA samples provided adequate numbers of leuko-
cytes for analysis; with neutropenic patients, multiple 4
mL aliquots of EDTA blood were processed individually,
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Control sera
Negative control reagents were provided by three
separate pools of serum from untransfused group AB
male donors, together with a sample of serum from a
single group AB donor. The positive control reagents
were comprised of a pool of multispecific HLA sera
(with at least five sera per pool, each serum having a
minimum of 85 percent panel reactivity in the lympho-
cytotoxicity test [LCT]). Other sera routinely applied
included an example of anti-NA1 and anti-NB1. The lat-
ter neutrophil-specific sera were used for simultaneous
typing of the patients under investigation and for con-
firming the NA1/NB1 types of the donors chosen for the
leukocyte panel.
Direct testing for bound IgG was achieved by incu-
bating the patients’ leukocytes with each of the four
negative control reagents described above. Indirect test-
ing for free antibodies in the patients’ serum was accom-
plished by incubating their sera (in parallel with the
negative control sera, the positive control multispecific
HLA reagent, and the two neutrophil-specific typing
reagents) against each of the mixed leukocyte samples
prepared from the normal donors selected for the leuko-
cyte antibody identification panel.
Flow cytometric analysis
Following staining with FITC-conjugated anti-IgG and
washing, the contents of individual wells were resus-
pended in 100 μL BSA/PBS/EDTA, transferred to an
appropriately sized test tube, an additional 400 μL of
buffer were added, and the contents were analyzed for
leukocyte-bound fluorescence using an Ortho Citoron
Absolute flow cytometer (Ortho Diagnostic Systems,
Loudwater, Buckinghamshire, UK). The different leuko-
cyte populations were discriminated on the basis of
their forward versus orthogonal light scatter properties,
and the intensity of granulocyte-, monocyte-, and lym-
phocyte-bound fluorescence was determined from his-
tograms derived from gates set around the different
leukocyte populations as identified by their light scatter
properties. As a rule, 20,000 events were collected.
Figure 1 depicts an example of a light-scatter dot plot,
and Figure 2 depicts histograms for negative and 
positive results with granulocytes and lymphocytes,
respectively.
Positive results in the GLAM test appear as a shift to
the right of appropriate fluorescence intensity his-
tograms (compare upper and lower panels in Fig. 2)
then pooled prior to incubation with the test sera
described below. Fixation was achieved by incubating
the 4 mL aliquots of prewarmed whole blood for 4 min-
utes with 4 mL of a 1:250 dilution of formol saline in PBS
prior to lysis of the fixed red blood cells through the
addition of 40 mL of Tris-buffered ammonium chloride
(1 g Tris-HCl plus 8.3 g ammonium chloride in 1 L dis-
tilled H2O; pH adjusted to 7.40) and incubation for 6
minutes at 37˚C in a waterbath.
The white cells were pelleted by centrifugation (400
g for 7 minutes), then washed in 0.5% bovine serum
albumin (BSA)/PBS buffer, and adjusted to a concentra-
tion of approximately 5 × 106/mL for incubation with
either control (positive or negative) sera or with the
patients’ sera. Usually, 50 μL of serum were incubated
for 45 minutes at 37˚C in a dry air incubator with equal
volumes of cell suspensions in U-bottomed microtiter
plates. After incubation, the cells were rewashed × 5,
incubated for 30 minutes in the dark at room tempera-
ture with a fluorescein isothiocyanate (FITC)-conjugat-
ed anti-human IgG reagent, then washed again × 3 prior
to analysis by flow cytometry. 
Nonspecific binding of the FITC conjugate was
assessed by testing against normal donor leukocytes that
had been incubated with four negative control reagents.
Table 1. Results of direct antiglobulin tests (direct GLAM) and autoanti-
body tests (indirect GLAM) and lymphocytotoxicity tests (LCT)
GRANULOCYTES LYMPHOCYTES
Case/Ref Direct Indirect Direct Indirect
GLAM GLAM GLAM GLAM LCT
1. CP Pos wk Neg Neg Neg Neg
2. RS Pos Neg Neg Neg Neg
3. CS Pos Neg Pos wk Neg ND‡
4. VB ND Pos ND Pos Neg
5. RM ND Pos* ND Pos* Neg
6. CW ND Pos* ND Pos* NT‡
7. SC ND Pos ND Neg Neg
8. VS ND Pos ND Neg NT
9. MG Neg Neg Pos Pos* Neg
10. JR Neg Neg Neg Neg† Neg
11. RW Neg Neg Neg Neg Neg
12. CB Neg Neg Neg Neg NT
13. RT Neg Neg ND Neg Neg
14. CM Neg Neg ND Neg NT
15. DM INC‡ Neg INC Neg Neg
16. AG ND Neg ND Neg NT
17. JG ND Neg ND Neg NT
18. HO ND Neg ND Neg NT
* Antibody subsequently disappeared on testing a further sample
† IgM anti-IgG blocking antibodies suspected; see text
‡ ND = not determined (insufficient sample); NT = not tested;
Inc = inconclusive because too few viable leukocytes were obtained to 
allow a conclusive analysis to be made
I M M U N O H E M A T O L O G Y ,  V O L U M E  1 2 ,  N U M B E R  4 ,  1 9 9 6166
A. LUBENKO AND S. WILSON
when comparing the fluorescent intensities (FLI)
observed with test sera with those obtained from the
negative control sera in the indirect test for free anti-
bodies. The FLI observed also can be compared with the
patient’s leukocytes with those observed with the panel
donor leukocytes after incubation with the negative
control reagents for the direct tests. Statistically, a posi-
tive result in the indirect test against a selected panel
donor sample would be indicated by an FLI value for the
test sample that exceeded the mean plus 2 SD of the FLI
value measured for the four negative control reagents
that were tested against that panel donor sample. A pos-
itive result in the direct test would be indicated by a
mean of the four FLI values measured with the patient’s
leukocytes (after incubation with the four negative con-
trol reagents) that exceeded the mean plus 2 SD of the
FLI values measured with all the panel donor leukocytes
after incubation with the four negative control reagents.
Results
Eighteen samples were referred for testing. The direct
GLAM test was performed on 10 of the 18 samples
(cases 1–3 and 9–15). Results on case 15 were incon-
clusive due to too few viable leukocytes for analysis. Of
the remaining nine samples, six had no detectable neu-
trophil-associated IgG in the DAT (see Direct test, Table
1, cases 9–14). In three of these six cases, no detectable
lymphocyte-associated IgG was found in the DAT (cases
10, 11, and 12), two of these six patients could not be
evaluated for conclusive analysis due to lymphocyte
insufficiency (cases 13 and 14), and one patient (case 9)
gave a positive result in the DAT with lymphocytes only
and was found to possess noncomplement-fixing lym-
phocyte antibodies free in the serum (see Indirect test,
Table 1). None of the other five patients (cases 10–14)
was found to have freely circulating lymphocyte- or
granulocyte-reactive IgG antibodies. However, serum
from one patient (case 10) prevented the detection of
B-cells (via surface IgG [sIgG]) with FITC anti-IgG in lym-
phocyte immunofluorescence intensity histograms, and
also obscured the presence of detectable FcR1-bound
IgG on monocytes with the FITC conjugate in monocyte
immunofluorescence intensity histograms. This may
have been due to an IgM anti-IgG antibody reacting with
the sIgG of the ß-cells and the FcR1-bound IgG of mono-
Fig. 2. Fluorescence intensity histograms of different leukocyte
populations gated as depicted in Figure 1. Top panels indi-
cate results achieved with negative control reagents; bot-
tom panels indicate typical examples of positive results.
The x-axis represents the fluorescent intensity (FLI) value
measured for the cells discriminated by the individual gates
shown in Figure 1. The y-axis indicates the number of cells
exhibiting a particular FLI value. The top of each individu-
al panel shows the number of events ( = number of cells)
within a particular gate that were analyzed for their FLI
value. L = histogram obtained after gating around lympho-
cytes; M = histogram obtained after gating around mono-
cytes; G = histogram obtained after gating around
granulocytes. Note the different positions of the various
“markers” set in each histogram for defining cutoffs for the
three leukocyte populations after incubation with FITC
conjugates; background fluorescence for monocytes
exceeds that for granulocytes which, in turn, is greater than
that for lymphocytes, perhaps reflecting the density and
affinity of the various FcR on the different cell types.
Fig. 1. Forward scatter (FW-SC, y-axis) versus right angle (aka
orthogonal scatter; RT-SC scatter, x-axis) dot plot showing
the three leukocyte populations. Region A = gate set
around lymphocytes; B = monocytes; C = granulocytes.
Statistics regarding the number of events and mean posi-
tions within the three gates are given in the listing to the
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antibodies were also detected (cases 4–6). Hence, in
these three cases at least, the antibody cannot be said to
have been granulocyte-specific. None of the five patients
provided enough granulocytes for testing for leukocyte-
bound antibodies which, when taken together with the
data from the three granulocyte DAT-positive patients
described above (cases 1–3), suggests that free antibod-
ies are generally detectable only when neutrophil
counts become extremely low.
The cohort of patients reported in this study gave
results that contrast with those from a previous study,2
in which seven of 13 evaluable patients presented with
DAT-positive granulocytes (compared with three of 10
in the present study), and four of 15 patients had gran-
ulocyte-specific free antibodies (compared with two of
18 here), with a further four of 15 patients having gran-
ulocyte-reactive and lymphocyte-reactive antibodies
free in the serum (compared with three of 18 here).
These differences might be influenced by (1) the rela-
tively small number of patients investigated, with a larg-
er number of patients being unevaluable for DAT testing
in the present study (eight patients compared with only
two patients in the previous study), and (2) differences
in practice and criteria for referral in regard to white cell
counts indicative of neutropenia, which can vary in dif-
ferent regions.
Nevertheless, two curious samples were encoun-
tered in the present study: one patient’s serum (case 10)
blocked the detection of B-cell sIgG and monocyte
FcR1-bound IgG; the other, (case 9), referred for inves-
tigation of a selective neutropenia rather than general-
ized pancytopenia, had an antibody detectable in the
GLAM using either autologous (direct test) or allogene-
ic (indirect test) lymphocytes as targets but not with
autologous or allogeneic granulocytes. Such unique find-
ings serve to emphasize the value of the GLAM test in
being able to provide analyses of antibody binding to
neutrophils and lymphocytes (and also monocytes,
when necessary) from a single donor tested in a single
test tube. This avoids the laborious repetitiveness that
would otherwise be inherent in successive direct and
indirect granulocyte, lymphocyte, and monocyte
immunofluorescence tests.
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cytes, thus blocking access to the FITC anti-IgG conju-
gate.
The three other patients from whom sufficient leuko-
cytes for DAT testing were harvested gave positive
results when tested for granulocyte-bound IgG (cases
1–3, Table 1). Of these, one patient (case 3) also pre-
sented with a weakly positive lymphocyte DAT. None of
the three patients in this cohort was found to have lym-
phocyte- or granulocyte-reactive antibodies free in the
serum.
Of the 18 referrals, too few leukocytes were harvest-
ed from nine patients to allow conclusive DAT testing
(cases 4–8 and 15–18 in Table 1). However, of this
cohort of nine patients, five had freely circulating neu-
trophil-reactive antibodies (cases 4–8) and three of the
five (cases 4–6) also had lymphocyte-reactive antibod-
ies. The specificities of these antibodies could not be
determined from the NA1 or NB1 types of the target cell
donors, and in three patients that were tested further
(case 4, 5, and 7), the antibodies were shown to be non-
complement fixing. Three of the nine patients (cases
16–18) had no detectable neutrophil- or lymphocyte-
reactive antibodies.
Discussion
The GLAM assay is now used at several laboratory
sites in the United Kingdom and has been shown to
withstand minor modifications in procedure, e.g.,
choice of microplates and use of alternative wash
buffers and conjugates, with no obvious deleterious
effects. In general, bypassing the need for preliminary
dextran sedimentation of red cells (when isolating gran-
ulocytes) reduces the turnaround time of the method
that, in conjunction with the fixation/red cell lysis
method described here, gives higher leukocyte yields so
that analyses usually can be made readily on patients
with neutrophil counts as low as 0.5 × 109/L.
In this current study, eight out of 18 patients (cases
1–8) referred for confirmation of a diagnosis of possible
autoimmune neutropenia were found to have either
granulocyte-associated IgG (three patients) or free gran-
ulocyte-reactive (presumed auto) antibodies (five
patients). In the first three patients, no free leukocyte
antibodies were detected, indicating that tests to con-
firm autoimmune neutropenia are unreliable if under-
taken purely on serum samples.
In three of the five patients with free granulocyte-
reactive antibodies (cases 4–8), free lymphocyte-reactive
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